Amgen Inc. Other Comprehensive Income (Loss), Net of Tax
Amgen Inc. (AMGN) reported Other Comprehensive Income (Loss), Net of Tax of $35.00 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2024-08-07
- Amgen Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was $35.00M.
- Amgen Inc. other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was $99.00M.
- Amgen Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $154.00M, a 670.00% increase year-over-year.
- Amgen Inc. other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was -$12.00M, a 113.19% decline year-over-year.
- Amgen Inc. other comprehensive income (loss), net of tax for fiscal 2023 was -$58.00M, a 110.27% decline from fiscal 2022.
- Amgen Inc. other comprehensive income (loss), net of tax for fiscal 2022 was $565.00M, a 198.94% increase from fiscal 2021.
- Amgen Inc. other comprehensive income (loss), net of tax for fiscal 2021 was $189.00M.
- Amgen Inc. other comprehensive income (loss), net of tax for fiscal 2020 was -$457.00M, a 289.63% decline from fiscal 2019.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2024-06-30 | $35.00M 10-Q · filed 2024-08-07 | $134.00M derived: sum of 2 quarters · filed 2024-08-07 | ||
| 2024-03-31 | $99.00M 10-Q · filed 2024-08-07 | |||
| 2023-12-31 | -$58.00M 10-K · filed 2024-02-14 | |||
| 2023-09-30 | $154.00M 10-Q · filed 2023-10-31 | $142.00M derived: sum of 2 quarters · filed 2024-08-07 | $105.00M derived: sum of 3 quarters · filed 2024-08-07 | |
| 2023-06-30 | -$12.00M 10-Q · filed 2024-08-07 | -$49.00M derived: sum of 2 quarters · filed 2024-08-07 | ||
| 2023-03-31 | -$37.00M 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $565.00M 10-K · filed 2024-02-14 | |||
| 2022-09-30 | $20.00M 10-Q · filed 2023-10-31 | $111.00M derived: sum of 2 quarters · filed 2023-10-31 | $144.00M derived: sum of 3 quarters · filed 2023-10-31 | |
| 2022-06-30 | $91.00M 10-Q · filed 2023-10-31 | $124.00M derived: sum of 2 quarters · filed 2023-10-31 | ||
| 2022-03-31 | $33.00M 10-Q · filed 2023-10-31 | |||
| 2021-12-31 | $189.00M 10-K · filed 2024-02-14 | |||
| 2021-09-30 | $60.00M 10-Q · filed 2022-11-04 | $25.00M derived: sum of 2 quarters · filed 2022-11-04 | $177.00M derived: sum of 3 quarters · filed 2022-11-04 | |
| 2021-06-30 | -$35.00M 10-Q · filed 2022-11-04 | $117.00M derived: sum of 2 quarters · filed 2022-11-04 | ||
| 2021-03-31 | $152.00M 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | -$457.00M 10-K · filed 2023-02-09 | |||
| 2020-09-30 | -$120.00M 10-Q · filed 2021-11-03 | -$241.00M derived: sum of 2 quarters · filed 2021-11-03 | -$375.00M derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | -$121.00M 10-Q · filed 2021-11-03 | -$255.00M derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | -$134.00M 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $241.00M 10-K · filed 2022-02-16 | |||
| 2019-09-30 | $77.00M 10-Q · filed 2020-10-29 | $128.00M derived: sum of 2 quarters · filed 2020-10-29 | $381.00M derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-06-30 | $51.00M 10-Q · filed 2020-10-29 | $304.00M derived: sum of 2 quarters · filed 2020-10-29 | ||
| 2019-03-31 | $253.00M 10-Q · filed 2020-10-29 | |||
| 2018-12-31 | -$81.00M 10-K · filed 2021-02-09 | |||
| 2018-09-30 | $64.00M 10-Q · filed 2019-10-30 | $185.00M derived: sum of 2 quarters · filed 2019-10-30 | -$121.00M derived: sum of 3 quarters · filed 2019-10-30 | |
| 2018-06-30 | $121.00M 10-Q · filed 2019-10-30 | -$185.00M derived: sum of 2 quarters · filed 2019-10-30 | ||
| 2018-03-31 | -$306.00M 10-Q · filed 2019-10-30 | |||
| 2017-12-31 | -$208.00M 10-K · filed 2020-02-12 | |||
| 2016-12-31 | $9.00M 10-K · filed 2019-02-13 | |||
| 2015-12-31 | -$472.00M 10-K · filed 2018-02-13 | |||
| 2014-12-31 | $153.00M 10-K · filed 2017-02-14 | |||
| 2013-12-31 | -$307.00M 8-K · filed 2016-10-31 | |||
| 2012-12-31 | -$25.00M 10-K · filed 2015-02-19 | |||
| 2011-12-31 | $18.00M 10-K · filed 2014-02-24 | |||
| 2010-12-31 | $108.00M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |